DNA2.0 Introduces Freedom Of Expression With A New Family Of Bacterial Expression Vectors
DNA2.0, the leading gene synthesis and protein engineering company, today introduced pJexpress—a new family of vectors for bacterial protein expression using either T7 or T5 promoters. Cloning into DNA2.0’s pJexpress vectors is performed at no additional cost for gene synthesis customers and provides the freedom of working with expression vectors that are not constrained by intellectual property restrictions. The pJexpress family of vectors is available now from DNA2.0 with the same speed and PhD-level support that customers have come to expect from the world’s fastest provider of synthetic genes. DNA2.0 will continue to develop new vectors with additional features in order to provide customers with the most advanced vector technology available.
"DNA2.0’s pJexpress vectors routinely express protein more efficiently than traditional pET vectors and without IP constraints associated with other bacterial expression vectors," said Claes Gustafsson, Vice President of Sales and Marketing for DNA2.0. "In keeping with our mission to facilitate cutting-edge research we are pleased to provide customers with a bacterial expression solution that is fast and highly cost efficient."
For more information about the choice of available pJexpress vectors, including data demonstrating the high levels of protein expression compared to pET vectors, customers may visit: www.DNA20.com/pJexpress.php
While many other gene synthesis companies offshore manufacturing to areas of the world with lax IP protection, all DNA2.0 genes are made at the company's state-of-the-art facility in Menlo Park, thus ensuring the greatest security for patented or confidential sequences. DNA2.0 guarantees researchers high quality synthetic genes, delivered on time, every time.
Founded in 2003, DNA2.0 is the leading synthetic biology company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 has provided genes to thousands of customers, for whom it has synthesized many millions of base pairs. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.